Forsta AP Fonden grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 5.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 384,500 shares of the biopharmaceutical company’s stock after purchasing an additional 19,600 shares during the period. Forsta AP Fonden’s holdings in Gilead Sciences were worth $26,381,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of GILD. Gilbert & Cook Inc. boosted its holdings in shares of Gilead Sciences by 5.3% in the fourth quarter. Gilbert & Cook Inc. now owns 6,791 shares of the biopharmaceutical company’s stock valued at $550,000 after acquiring an additional 344 shares in the last quarter. Aveo Capital Partners LLC boosted its stake in Gilead Sciences by 8.6% during the 4th quarter. Aveo Capital Partners LLC now owns 5,473 shares of the biopharmaceutical company’s stock valued at $443,000 after purchasing an additional 435 shares in the last quarter. Cary Street Partners Investment Advisory LLC increased its position in shares of Gilead Sciences by 47.2% during the 4th quarter. Cary Street Partners Investment Advisory LLC now owns 6,313 shares of the biopharmaceutical company’s stock valued at $511,000 after purchasing an additional 2,024 shares during the period. Jump Financial LLC raised its stake in shares of Gilead Sciences by 141.2% in the 4th quarter. Jump Financial LLC now owns 7,148 shares of the biopharmaceutical company’s stock worth $579,000 after buying an additional 4,184 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its holdings in shares of Gilead Sciences by 4.8% in the fourth quarter. Janney Montgomery Scott LLC now owns 231,819 shares of the biopharmaceutical company’s stock valued at $18,780,000 after buying an additional 10,577 shares during the period. 83.67% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In related news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The sale was disclosed in a document filed with the SEC, which is available at this link. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now directly owns 96,380 shares in the company, valued at $6,614,559.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the sale, the insider now directly owns 114,979 shares of the company’s stock, valued at $8,506,146.42. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.
Analysts Set New Price Targets
Read Our Latest Stock Analysis on GILD
Gilead Sciences Price Performance
NASDAQ GILD opened at $80.94 on Thursday. The company has a 50 day simple moving average of $74.82 and a 200-day simple moving average of $70.72. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $87.86. The firm has a market capitalization of $100.77 billion, a price-to-earnings ratio of 224.83, a price-to-earnings-growth ratio of 2.73 and a beta of 0.18. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The company had revenue of $6.95 billion during the quarter, compared to analyst estimates of $6.64 billion. Equities research analysts predict that Gilead Sciences, Inc. will post 3.78 earnings per share for the current fiscal year.
Gilead Sciences Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be paid a $0.77 dividend. The ex-dividend date is Friday, September 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.81%. Gilead Sciences’s dividend payout ratio (DPR) is currently 855.56%.
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
- Five stocks we like better than Gilead Sciences
- Investing in Construction Stocks
- Goldilocks CPI Report Leads Market to Sell Off, Lower Lows Ahead
- Retail Stocks Investing, Explained
- GameStop: Earnings Won’t Save It, Dilution Points to Trouble
- Why Invest in 5G? How to Invest in 5G Stocks
- Dividend Aristocrats or Dividend Kings: Which Is Best for You?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.